PA
SYRS

Perceptive Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Perceptive Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-116,754
Closed -$251K – 127
2024
Q3 		$251K Hold
116,754
– – 0.01% 104
2024
Q2 		$602K Hold
116,754
– – 0.01% 104
2024
Q1 		$625K Buy
+116,754
New +$807K 0.01% 108

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Perceptive Advisors's SYRS Position: Q4 2024 in Review

Perceptive Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 116,754 shares — an estimated $251K sold.

Perceptive Advisors first reported a position in SYRS in Q1 2024 and held it in 3 quarters. The position peaked at $625K in Q1 2024. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

  • Perceptive Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Perceptive Advisors sold 116,754 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $251K.
  • Perceptive Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2024 and held it in 3 quarters.
  • Perceptive Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $625K in Q1 2024.
  • 44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.